Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale10b5-1 plan | 06/22 | 06/24 | 10,000 sh | $35.01 | $350,100 | −7.2% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 06/08 | 06/09 | 5,222 sh | $27.30 | $142,560.6 | −3.6% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale10b5-1 plan | 05/08 | 05/11 | 10,000 sh | $30.00 | $300,000 | −6.9% |
UroGen PharmaURGN | Open-market sale | 02/03 | 02/11 | 7,479 sh3 trades | $19.69avg. | $147,261.51 | −11.9% | |
UroGen PharmaURGN | Open-market sale | 02/03 | 02/04 | 7,373 sh3 trades | $19.69avg. | $145,174.37 | −4.8% | |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale10b5-1 plan | 25/11/19 | 25/11/20 | 10,000 sh | $25.00 | $250,000 | −6.7% |
Chris DegnanCFO | UroGen PharmaURGN | Open-market sale | 25/10/08 | 25/10/09 | 2,203 sh | $16.85 | $37,120.55 | −49.1% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 25/09/08 | 25/09/09 | 871 sh | $19.11 | $16,644.81 | −0.6% |
Jason Drew SmithGeneral Counsel | UroGen PharmaURGN | Open-market sale | 25/09/08 | 25/09/09 | 1,520 sh | $19.11 | $29,047.2 | −3.4% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 25/08/11 | 25/08/13 | 10,000 sh | $17.69 | $176,900 | −6.3% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 25/07/28 | 25/07/30 | 5,149 sh | $19.14 | $98,551.86 | −3.2% |
Jason Drew SmithGeneral Counsel | UroGen PharmaURGN | Open-market sale | 25/07/28 | 25/07/30 | 7,522 sh | $19.14 | $143,971.08 | −15.3% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 25/06/09 | 25/06/11 | 5,162 sh | $7.37 | $38,043.94 | −3.3% |
UroGen PharmaURGN | Open-market sale | 25/01/31 | 25/02/04 | 4,551 sh3 trades | $11.14avg. | $50,698.14 | −3.0% | |
UroGen PharmaURGN | Open-market sale | 25/01/31 | 25/02/04 | 7,379 sh3 trades | $11.14avg. | $82,202.06 | −18.5% | |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 24/09/09 | 24/09/12 | 859 sh | $13.08 | $11,235.72 | −0.6% |
Jason Drew SmithGeneral Counsel | UroGen PharmaURGN | Open-market sale | 24/09/09 | 24/09/12 | 1,521 sh | $13.08 | $19,894.68 | −5.7% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 24/06/10 | 24/06/11 | 5,153 sh | $13.08 | $67,401.24 | −3.4% |
Mark SchoenbergChief Medical Officer | UroGen PharmaURGN | Open-market sale | 24/03/18 | 24/03/20 | 12,000 sh | $14.05 | $168,600 | −7.9% |
UroGen PharmaURGN | Open-market saleAmendment | 24/02/01 | 24/02/05 | 3,789 sh3 trades | $15.78avg. | $59,790.42 | −2.4% |